Ocean Biomedical, Inc.

OCEAdata completeness 63%3 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'capex'; no data for concept 'incomeTaxExpense'; no data for concept 'pretaxIncome'

i. The business — what you’d actually own

Figure	FY 2022	FY 2023	FY 2024
Revenue	—	—	—
Net income	−$17.4M¹	−$114.5M²	−$9.48M²
Operating cash flow	−$993,000³	−$9.43M⁴	−$4.18M⁴
Capital expenditure	—	—	—
Free cash flow (derived)	—	—	—
Total debt	—	$3.2M⁵	—
Cash & equivalents	—	$1M⁶	$200,000⁷
Diluted shares	23.4M	26.3M	27.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$35.49

your share of equity

Profit it earned you last year

−$3.45

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$35.49 of net worth that earned you −$3.45 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 3y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

+18% shares · 3y

Share count is up 18% over 3 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts